



Leukemia & Lymphoma >

Volume 56, 2015 - Issue 4

250 | 3
Views | CrossRef citations to date | Altmetric

Original Article: Clinical

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

Eric Jacobsen Olga Pozdnyakova, Robert Redd, David C. Fisher, David M. Dorfman, Paola Dal Cin, [... show all](#)

Pages 993-998 | Received 03 Jun 2014, Accepted 30 Jun 2014, Accepted author version posted online: 11 Jul 2014, Published online: 20 Aug 2014

Cite this article <https://doi.org/10.3109/10428194.2014.941835>

Check for updates

Sample our 
Medicine, Dentistry, Nursing
& Allied Health Journals
**>> [Sign in here](#) to start your access
to the latest two volumes for 14 days**

Full Article

Figures & data

References

Supplemental

Citations

Metrics

Reprints & Permissions

Read this article

Share

Abstract

Platelet derived growth factor- α (PDGFR- α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR- α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR- α fusion and/or PDGFR- α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis

of PDGFR- α by immunohistochemistry and three of these patients' tumors expressed PDGFR- α . Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR- α expression was not required for study entry.

Keywords::

Lymphoma imatinib PDGFR- α

Potential conflict of interest:

[Disclosure](#) forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Related research

People also read

Recommended articles

Cited by
3

Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources
by email

 Sign me up

  

  

Copyright © 2026 Informa UK Limited Privacy policy Cookies Terms & conditions

Accessibility



Registered in England & Wales No. 01072954
5 Howick Place | London | SW1P 1WG